Never miss an update from Universitat de Lleida
Create your free account to connect with Universitat de Lleida and thousands of other innovative organizations and professionals worldwide
A group of researchers in the University of Lleida have preclinical evidence for the positive effects of a peptide administration in the mouse model for ALS (mSOD1G93A mice). When treated with a solution containing interleukin-4 polypeptide (IL4), the team is able to prolong survival, delay the manifestation of the most apparent symptoms of the disease and improve the clinical course of the disease attenuating body weight loss and improving the motor behavior.
The University of Lleida seeks an industrial partner willing to further develop this technology under a license agreement.
ALS is devastating neurodegenerative disorder. It’s a debilitating and life-threatening disease because of the gradual loss of function and its paralyzing effect on muscles used for breathing, which usually leads to death from respiratory failure. The average life expectancy of ALS patients after diagnosis is between 2-5 years.
There is currently no cure for ALS. There only exist two approved ALS medicine: riluzole (Rilutek®), modestly slows the progression of the disease in some people and the recently approved edaravone (Radicava®) reduces the rate of functional decline in these patients. Treatments focus on the alleviation of symptoms, and possibly slowing down the rate of ALS progression.
Chronic administration of recombinant IL4 to ALS preclinical model ( mSOD1G93A mice) leads to:
Current development status
Experimental technologies
Desired business relationship
We are looking for an industrial partner willing to adopt a new technology for ALS treatment. The type of partner sought is for the clinical development of the protected technology under a license agreement.
Patent licensing
Technology codevelopment
New technology applications
Applications
With the main aim to minimize or even erase the progression of ALS, the goal would be to develop a more effective therapeutic treatment than those currently available. Our solution could be also developed as a combination product with other therapeutic agents showing promising outcomes.
The Valorisation and Technology Transfer Unit (UViT) is the specialized unit for handling the IPR portfolio in the University of Lleida. The UViT works close to researchers in the fields of Agrifood, Biomedicine, Technology and Sustainability and Social Development to identify research results with market potential, to assess the community on the best IP protection strategy and to commercialise technologies through licensing-out agreements and the creation of technology-based companies.
Create your free account to connect with Universitat de Lleida and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universitat de Lleida
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support